Dr. Tarsheen Sethi
Claim this profileYale University
Area of expertise
T-Cell Lymphoma
Tarsheen Sethi has run 2 trials for T-Cell Lymphoma. Some of their research focus areas include:
Cutaneous T-Cell Lymphoma
Tarsheen Sethi has run 2 trials for Cutaneous T-Cell Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Yale University
Clinical Trials Tarsheen Sethi is currently running
Pembrolizumab + Brentuximab
for T-Cell Lymphoma
This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell lymphoma) who have received at least one prior therapy. We hypothesize that this combination is effective and will produce an overall response rate of \~55%. Pembrolizumab and brentuximab will be administered for 16 cycles in subjects with responsive disease. Pembrolizumab will be continued for an additional 19 cycles (total 35 cycles). Response assessments will occur at pre-specified intervals. For the primary endpoint the response assessment after 3 cycles will be taken into consideration. Dose adjustments for specific toxicities with either drug are detailed in the protocol. Based on statistical analysis 32 subjects will need to be accrued to evaluate for disease response based on historical control.
Recruiting
1 award
Phase 2
Tazemetostat + Belinostat
for Lymphoma
This phase I trial tests the safety, side effects, and best dose of combination therapy with tazemetostat and belinostat in treating patients with lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Tazemetostat is in a class of medications called EZH2 inhibitors. The EZH2 gene provides instructions for making a type of enzyme called histone methyltransferase which is involved in gene expression and cell division. Blocking EZH2 may help keep cancer cells from growing. Belinostat is in a class of medications called histone deacetylase inhibitors. Histone deacetylases are enzymes needed for cell division. Belinostat may kill cancer cells by blocking histone deacetylase. It may also prevent the growth of new blood vessels that tumors need to grow and may help make cancer cells easier to kill with other anticancer drugs. There is some evidence in animals and in living human cells that combination therapy with tazemetostat and belinostat can shrink or stabilize cancer, but it is not known whether this will happen in people. This trial may help doctors learn more about treatment of patients with relapsed or refractory lymphoma.
Recruiting
1 award
Phase 1
More about Tarsheen Sethi
Clinical Trial Related
2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Tarsheen Sethi has experience with
- Brentuximab Vedotin
- Pembrolizumab
- Belinostat
- Tazemetostat
Breakdown of trials Tarsheen Sethi has run
T-Cell Lymphoma
Cutaneous T-Cell Lymphoma
Peripheral T-Cell Lymphoma
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tarsheen Sethi specialize in?
Tarsheen Sethi focuses on T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. In particular, much of their work with T-Cell Lymphoma has involved CD30 positive patients, or patients who are EZH2 negative.
Is Tarsheen Sethi currently recruiting for clinical trials?
Yes, Tarsheen Sethi is currently recruiting for 2 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Tarsheen Sethi has studied deeply?
Yes, Tarsheen Sethi has studied treatments such as Brentuximab vedotin, Pembrolizumab, Belinostat.
What is the best way to schedule an appointment with Tarsheen Sethi?
Apply for one of the trials that Tarsheen Sethi is conducting.
What is the office address of Tarsheen Sethi?
The office of Tarsheen Sethi is located at: Yale University, New Haven, Connecticut 06520 United States. This is the address for their practice at the Yale University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.